Description
Tazverik (tazemetostat) is used to treat epithelioid sarcoma in adults and teens aged 16+. It’s intended to reduce the growth of cancer cells. Doctors typically prescribe it when the cancer has spread or is locally advanced and cannot be fully removed with surgery.
Additionally, this medication is used to treat follicular lymphoma in adults when the disease has come back or hasn't responded to treatment. For example, it may be selected if the tumor has an EZH2 mutation, the person has received at least 2 prior systemic therapies, or there are no satisfactory alternative treatment options.
Tazverik works by blocking an enzyme called EZH2, as well as certain mutated forms of it. EZH2 helps control which genes are turned on or off in cells.
| Fact Table |
| Formula |
Tazemetostat: C34H44N4O4; tazemetostat hydrobromide: C34H44N4O4·HBr |
| License |
US FDA accelerated approval; voluntarily withdrawn/discontinued in U.S. in 2026; Japan approval listed |
| Bioavailability |
Approximately 33% |
| Legal status |
Rx-only; discontinued/withdrawn from U.S. market in 2026 |
| Chemical Name |
[1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) |
| Elimination half-life |
Approximately 3.1 hours at steady state |
| Dosage (Strength) |
200 mg tablet; recommended dose was 800 mg orally twice daily with or without food; each 200 mg tablet is equivalent to 228 mg tazemetostat hydrobromide |
| Pregnancy |
Can cause fetal harm; avoid during pregnancy and consult a doctor |
| Brands |
Tazverik |
| Protein binding |
88% |
| PubChem CID |
Tazemetostat: 66558664; tazemetostat hydrobromide: 71761627 |
| MedlinePlus |
a620018 |
| ChEBI |
231598 |
| ATC code |
L01XX72 |
| DrugBank |
DB12887 |
| KEGG |
D11444; D11485 (tazemetostat hydrobromide) |
| Routes of administration |
Oral |
Directions
After you buy Tazverik with a valid prescription, your doctor will typically advise you to take it twice daily by mouth, with or without food.
The usual starting dose is 800 mg daily, split into 4 tablets of 200 mg each. Swallow the tablets whole and do not chew, crush, or split them.
If you miss a dose of Tazverik or vomit after taking the medication, don’t take an extra dose. Instead, take your next dose at the usual time.
If you experience side effects, your provider may lower your dose or stop the treatment. Patients usually take this medication until the cancer gets worse or side effects become too severe. Always take this medication as directed by your provider.
Ingredients
The active ingredient in Tazverik is tazemetostat.
Cautions
Tazverik may increase your risk of developing new cancers, including certain blood cancers. Your care team may monitor you during treatment.
Inform your doctor immediately if you are pregnant or suspect you are pregnant, as this medication can harm an unborn baby.
Tazverik can make certain hormonal birth control less effective. Use effective non-hormonal birth control during treatment if you can become pregnant. Continue for 6 months after your last dose.
If you are male with a partner who can become pregnant, use effective birth control during treatment and for at least 3 months after your last dose.
Do not breastfeed while taking Tazverik and wait for one week after your last dose.
Avoid taking Tazverik with strong or moderate CYP3A inhibitors. If these medications can’t be avoided, your provider may lower your dose. Taking Tazverik with strong or moderate CYP3A inducers isn’t recommended.
Let your doctor know if you have moderate or severe liver impairment. Although Tazverik hasn’t been studied in this population, your prescriber may consider this information when deciding if this medication is suitable for you.
Inform your doctor if you have severe kidney impairment or end-stage kidney disease. Even though no dose change is recommended, your doctor should be aware of any additional health conditions.
Contraindications
According to the FDA, there are no known contraindications.
Side Effects
Relatively common but typically manageable side effects include fatigue, nausea, vomiting, constipation, and upper respiratory tract infections.
More serious side effects include secondary cancers (including blood cancers), harm to an unborn baby, serious bleeding, serious infections (such as sepsis and pneumonia), and low blood counts.
This is not a complete list of Tazverik side effects. Contact your doctor if you notice any persistent or concerning side effects from Tazverik, or if you have any questions about Tazverik’s price, coverage, and more.
Buy Tazverik today at a low price!
References
-
TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc.; 2024.
-
TAZVERIK (tazemetostat) Follicular Lymphoma Patient Website. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; 2025.
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 15509
Prescription Required